Stephanie Braga Gonçalves da Silva
Research Subjects
Research Interests
Stephanie Braga Gonçalves da Silva has a total of 10 co-authors. Here are the top co-authors by number of shared publications:
- Aline Luiza Costa e Silva1 shared publication
- Ana Beatriz Ramos Do Nascimento
Instituto René Rachou - Fiocruz Minas, Belo Horizonte, Minas Gerais, Brazil / Instituto Mário Penna de Ensino, Pesquisa e Inovação - Laboratório de Pesquisa Translacional em Oncologia, Belo Horizonte, Minas Gerais, Brazil
1 shared publication - Anna Carolina Almeida de Paula1 shared publication
- Eduardha Santos Temponi Barroso
Universidade Federal de Minas Gerais, Brazil
1 shared publication Jorge Gomes Goulart Ferreira
1 shared publication- Paulo Guilherme de Oliveira Salles
INSTITUTO MÁRIO PENNA
1 shared publication
Latest Publications
- Open Access
- 23 October 2025
- Published by Instituto Mário Penna in Mário Penna Journal
- Vol. 2 (2) , 29-40
Evaluation of the OvarianTag biomarker panel's applicability in detecting Krukenberg tumors.
Krukenberg tumor is a metastatic ovarian adenocarcinoma, typically originating from the gastrointestinal tract, especially gastric cancer. It accounts for a significant proportion of ovarian tumors, being more common in Asian populations. These tumors usually affect younger women and have a poor prognosis. Diagnosis is challenging due to clinical similarities with other ovarian cancers, requiring a multimodal approach, including imaging tests, histopathological analysis, and biochemical markers. CA-125 may be useful in diagnosis but lacks specificity. Identifying molecular biomarkers specific to Krukenberg tumors could improve diagnosis and treatment. This study investigated the use of the OvarianTag® biomarker panel, developed to assess the prognosis of epithelial ovarian cancer (EOC), to differentiate between primary ovarian cancers and metastatic tumors from other sites, such as those from gastrointestinal origin. The research analyzed Krukenberg tumor samples and primary ovarian cancer samples, utilizing RNA extracted from tumor tissues and gene expression analysis by RT-qPCR. Despite genetic analysis, the OvarianTag® algorithm was unable to distinguish Krukenberg tumors from primary ovarian cancers accurately. The expression of genes TNFSRF10B, TNFSRF10C, and CASP8 showed no significant differences between the groups, and the algorithm failed to classify Krukenberg tumors correctly. These results suggest that OvarianTag® is not effective for this specific application, highlighting the need for new biomarkers to improve the diagnosis of metastatic ovarian tumors.
- 23 October 2025
- Published by Instituto Mário Penna in Mário Penna Journal
- Vol. 2 (2) , 29-40
Open AccessEvaluation of the OvarianTag biomarker panel's applicability in detecting Krukenberg tumors.
Krukenberg tumor is a metastatic ovarian adenocarcinoma, typically originating from the gastrointestinal tract, especially gastric cancer. It accounts for a significant proportion of ovarian tumors, being more common in Asian populations. These tumors usually affect younger women and have a poor prognosis. Diagnosis is challenging due to clinical similarities with other ovarian cancers, requiring a multimodal approach, including imaging tests, histopathological analysis, and biochemical markers. CA-125 may be useful in diagnosis but lacks specificity. Identifying molecular biomarkers specific to Krukenberg tumors could improve diagnosis and treatment. This study investigated the use of the OvarianTag® biomarker panel, developed to assess the prognosis of epithelial ovarian cancer (EOC), to differentiate between primary ovarian cancers and metastatic tumors from other sites, such as those from gastrointestinal origin. The research analyzed Krukenberg tumor samples and primary ovarian cancer samples, utilizing RNA extracted from tumor tissues and gene expression analysis by RT-qPCR. Despite genetic analysis, the OvarianTag® algorithm was unable to distinguish Krukenberg tumors from primary ovarian cancers accurately. The expression of genes TNFSRF10B, TNFSRF10C, and CASP8 showed no significant differences between the groups, and the algorithm failed to classify Krukenberg tumors correctly. These results suggest that OvarianTag® is not effective for this specific application, highlighting the need for new biomarkers to improve the diagnosis of metastatic ovarian tumors.